Mesirow Financial Investment Management Equity Management maintained its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the second quarter, Holdings Channel reports. The institutional investor owned 25,125 shares of the life sciences company’s stock at the end of the second quarter. Mesirow Financial Investment Management Equity Management’s holdings in Integra LifeSciences Holdings Corporation were worth $1,369,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in IART. Koch Industries Inc. acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth approximately $250,000. First Mercantile Trust Co. acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth approximately $279,000. State of Alaska Department of Revenue increased its stake in Integra LifeSciences Holdings Corporation by 80.1% in the second quarter. State of Alaska Department of Revenue now owns 11,939 shares of the life sciences company’s stock worth $650,000 after buying an additional 5,309 shares during the last quarter. Columbus Circle Investors acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth approximately $18,875,000. Finally, Wells Fargo & Company MN increased its stake in Integra LifeSciences Holdings Corporation by 18.0% in the first quarter. Wells Fargo & Company MN now owns 2,467,892 shares of the life sciences company’s stock worth $103,972,000 after buying an additional 375,857 shares during the last quarter. Institutional investors own 86.77% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at 49.81 on Thursday. The stock’s 50 day moving average is $52.89 and its 200-day moving average is $46.88. The firm has a market cap of $3.89 billion, a P/E ratio of 60.74 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a one year low of $40.51 and a one year high of $88.86.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.45. The business had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.40 earnings per share. Analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Position Held by Mesirow Financial Investment Management Equity Management” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-position-held-by-mesirow-financial-investment-management-equity-management/1469132.html.

A number of analysts have commented on IART shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. ValuEngine downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Jefferies Group LLC increased their price objective on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the company a “buy” rating in a report on Friday, April 28th. Finally, Oppenheimer Holdings, Inc. set a $54.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Monday, May 15th. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Integra LifeSciences Holdings Corporation currently has a consensus rating of “Buy” and a consensus target price of $52.63.

In related news, Director Stuart Essig sold 135,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the completion of the transaction, the director now owns 2,077,475 shares of the company’s stock, valued at $103,666,002.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara B. Hill purchased 5,050 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average cost of $49.33 per share, with a total value of $249,116.50. Following the transaction, the director now directly owns 44,772 shares of the company’s stock, valued at approximately $2,208,602.76. The disclosure for this purchase can be found here. Insiders have purchased 17,550 shares of company stock worth $864,842 in the last three months. Insiders own 21.50% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.